U.S. prostate cancer therapeutics market, by drug class, 2014 - 2025 (USD Billion) |
The global prostate CancerTherapeutics market is expected to reach USD 12.0 billion by
2025, according to a new report by Grand View Research, Inc. According to the
American Cancer Society, approximately 1 in 7 men will be diagnosed with
prostate cancer in their lifetime. As per Cancer Research, a government
institute, in the UK, 46,690 new cases of prostate cancer were diagnosed out of
which 11,287 patients died in 2014.
Supportive initiatives undertaken by key players in collaboration with
various governments to create more awareness of clinical symptoms about
prostate cancer and availability of screening & diagnostic tests such as
Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in
early detection. Early detection helps in quick and on time treatment and
assists in deciding treatment regimens. In addition, major players including
Astella, Inc., Sanofi, Dendreon Corporation, AstraZeneca, and Johnson &
Johnson are focusing on development of effective and safe therapeutic products
to treat tumor. Moreover, these players have various established brands such as
Zytiga, Xtandi, Eligard, Taxotere, Provenge, and Xofigo, which hold a strong
position in the market. In addition, there are many drugs in pipeline such as
Tc-99m (Progenics), radium-223 dichloride (Xofigo, Bayer), and ODM-201 (Orion
and Bayer), which are in their phase 3 studies and are expected to enter the
market during the forecast period. In addition, patents of many existing
products are expiring during the forecast period. As a result, generic products
are anticipated to penetrate the market. All these factors together are
expected to propel growth.
In Canada, Prostate Cancer Foundation of Canada supports research, cure,
and prevention of prostate cancer through an online portal. This portal
provides detailed information regarding symptoms, diagnosis, and commercially
available treatment options. Such portals offer free access to people all
around the world, which is resulting in growth.
Full
Research Report On Prostate Cancer Therapeutics Market Analysis:
https://www.grandviewresearch.com/industry-analysis/prostate-cancer-therapeutics-market
https://www.grandviewresearch.com/industry-analysis/prostate-cancer-therapeutics-market
Further key findings from the study suggest:
·
The growing incidence of prostate cancer
across the globe is expected to drive growth
·
The market is segmented into hormonal
therapy including Luteinizing Hormone Releasing Hormone (LHRH) agonist, LHRH antagonist
& antiandrogen; chemotherapy; immunotherapy, and targeted therapy
·
Zytiga (Johnson & Johnson) is
considered as a gold standard product for the treatment of prostate cancer and
holds a strong position. However, Xtandi (Astella, Inc.) and Zytiga are
competing with each other. The degree of competition is projected to elevate
during the forecast period. Thus, hormonal therapy holds the largest share.
·
Provenge (Dendreon Corporation) is the only
immunotherapy drug mainly used in the treatment of advanced or metastasis of
such cancerous cells
·
In addition, there are many promising
immunotherapy drugs in the pipeline such as INO-5150 SynCon and PROSTVAC
(Bavarian Nordic), which are expected to enter the market in the near future.
Thus, this drug class is projected to be the fastest growing segment.
·
North America dominated the global market.
Rising prevalence and mortality rate associated with such tumors in the U.S. is
the primary reason for the dominance of the region.
·
Asia Pacific is anticipated to be the
fastest growing region over the forecast period. Rising awareness regarding
prostate cancer in Asian countries including China, Japan, & India, would
be the major factor driving the growth.
·
Some of the major players include, but are
not limited to, Johnson & Johnson; Astella, Inc.; Sanofi; Ipsen; Bayer AG;
AstraZeneca; Valeant Pharmaceuticals North America LLC (Dendreon Corporation).
These major players dominate the market owing to their strong brand identity
and extensive geographic reach.
View More Reports
Of This Category By Grand View Research At: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the prostate cancer therapeutics
market by drug and region:
Drugs Outlook (Revenue, USD
billion; 2014 - 2025)
·
Hormonal Therapy
o Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
o Zytiga
o Gonax
o Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
o Lupron
o Zoladex
o Eligard
o Decapeptyl
o Vantas
o Others
o Anti-Androgen
o Xtandi
o Casodex
o Chemotherapy
o Taxotere
o Jevtana
o Immunotherapy
o Provenge
o Targeted Therapy
o Xofigo
Regional Outlook (Revenue,
USD billion; 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o China
o Japan
·
Latin America
o Mexico
o Brazil
·
MEA
o South Africa
Access Full Press Release of this
Report:
https://www.grandviewresearch.com/press-release/global-prostate-cancer-therapeutics-market
https://www.grandviewresearch.com/press-release/global-prostate-cancer-therapeutics-market
About Grand View
Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/
No comments:
Post a Comment